Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous pertuzumab + trastuzumab with docetaxel and carboplatin as neoadjuvant therapy for HER2-positive breast cancer
ChiCTR2500106240Phase 4Not yet recruiting
- Sponsor
- Chongqing General Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pertuzumab and trastuzumab in breast cancer, sponsored by Chongqing General Hospital. Primary endpoint: Pathological complete response rate (pCR). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500106240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106240.